| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-03-0937.
BRIEF REPORT
From the Department of Hematopoiesis and the Flow
Cytometry Facility, Jerome H. Holland Laboratory for the Biomedical
Sciences, American Red Cross, Rockville, MD, and Department of Anatomy
and Cell Biology, The George Washington University Medical Center,
Washington, DC.
Hematopoiesis initiates in the extraembryonic yolk sac. To
isolate various types of precursor cells from this blood cell-forming tissue, yolk sac cells were immortalized by retroviral-mediated expression of the HOX11 homeobox-containing gene. Among the
cell lines derived, some were able to spontaneously generate adherent stromal-like cells capable of taking up acetylated low-density lipoprotein, and they could be induced to form tubelike structures when
cultured on Matrigel. Although these cell lines were negative for
hematopoietic cell surface markers, they gave rise to hematopoietic colonies Analyses of the early stages of murine
embryonic development have shown that hematopoietic activity originates
in the extraembryonic yolk sac and the aorta, gonads, and mesonephros.
These locations remain the primary sites of hematopoiesis until
approximately 12 postcoitum days (dpc) when the fetal liver becomes the
predominant hematopoietic organ. In yolk sac, the earliest stage of
hematopoietic development is localized in the blood islands, which
consist of 2 lineages: a population of hematopoietic cells, surrounded
by a layer of angioblasts. The simultaneous appearance of both
hematopoietic and endothelial lineages in close proximity within the
yolk sac blood islands indicates that hematopoietic and endothelial
cells might be derived from the same precursor cell
population.1
Further understanding of the origin of the hematopoietic lineage
and the mechanisms involved in hematopoietic cell differentiation requires access to various precursor cell subsets. In the mouse, such
studies are difficult as the embryo is extremely small at this time,
hindering the ready isolation and characterization of transient cell
populations. To circumvent this problem, we sought to establish
permanent cell lines representative of the various types of precursors
present in the yolk sac during this limited temporal period.
HOX11, a homeobox-containing gene 2-4 having
strong immortalizing potential for bone marrow5,6 as well
as embryonic stem (ES) cell-derived7,8 hematopoietic cells, was used to transduce yolk sac cells by retroviral-mediated gene
transfer. This approach resulted in immortalization of 2 distinct types
of yolk sac cell populations.
Immortalization of yolk sac cells with a HOX11
retroviral vector
Hematopoietic differentiation of type I yolk sac precursor
cells
In vitro angiogenesis assay For the in vitro angiogenesis assay,12,13 Matrigel (BD Biosciences, Bedford, MA) containing a full combination of growth factors including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) was thawed at 4°C overnight and wells of 24-well plates were coated with 300 µL liquid per well. The coated wells were then incubated at 37°C for 30 minutes and 2.5 × 104/mL HOX11-immortalized cells were seeded into each well in RPMI 1640 medium containing 15% FBS. After 3 to 4 days of incubation, morphologic changes of the cells were recorded under the microscope.
To isolate precursor cells representative of various developmental stages from yolk sac, cell suspensions from individual yolk sacs at 9.0 to 9.5 dpc were transduced with a HOX11 retroviral vector.5,7,8 As a result of HOX11 expression, each yolk sac gave rise to a permanent cell line, whereas nontransduced yolk sac cells ceased growing after several passages. Interestingly, among the 34 cell populations immortalized, 8 (designated as type I) were capable of continuously producing both plastic-adherent, endothelial-like cells as well as nonadherent suspension cells in the liquid culture procedures described in "Study design." This phenotype differs from that of the HOX11-immortalized bone marrow-derived5,6 and ES cell-derived hematopoietic cells7 obtained previously. The remaining 26 cell populations (designated as type II) contained strictly hematopoietic suspension cells that lacked this property. The immortalization procedure was repeated using 8.0 to 8.5 dpc and 10.0 to 10.5 dpc yolk sac cells, yielding similar results (data not shown). Single-cell cloning of all type I cell populations through limiting
dilution resulted in a 60% ± 7% frequency of colony generation, all of which were composed of adherent, stromal-like cells as well as
suspension cells (Figure 1A). Type I
precursor cell populations were subsequently subcloned in the same
manner. All subclones generated from 8 parental cell populations showed
very similar morphology and biologic properties. Morphologic
examination of cytospin samples revealed that they consisted of
homogeneous populations of immature blastlike cells (Figure 1B).
The hematopoietic potential of type I precursor cells was first examined. After 10 to 12 days of culture, homogeneous compact colonies arose in the hematopoietic growth factor-containing methylcellulose cultures. Morphology of the cytospin preparations of the compact colonies showed a striking difference from that of the parental cell lines. The compact colonies were composed of differentiating hematopoietic cells corresponding to a variety of lineages, including definitive erythroid cells and macrophages, in addition to undifferentiated blastlike cells (Figure 1C). Fluorescence-activated cell sorting (FACS) analyses of hematopoietic lineage markers demonstrated that cells expressing Ter-119, Mac-1, and B220, but not Gr-1 or CD4, had developed within the compact colonies (Figure 1D), in contrast to the completely negative expression of these markers on the parental cell lines (see below). To better examine the hematopoietic differentiation potential of the precursor cells, a 2-stage culture protocol was used. Compact colonies generated during the first stage of culturing were harvested, dissociated, and replated under the same conditions. After a further 7 to 10 days of incubation, diverse colony types were observed. In addition to secondary compact colonies that were derived from the remaining undifferentiated or self-renewed precursor cells in the primary compact colonies, a variety of hematopoietic progenitor-derived colonies such as definitive erythroid colony-forming unit (Ery-D), macrophage colony-forming unit (CFU-M), and megakaryocyte colony-forming unit (CFU-Mk) colonies had formed (Figure 1E). As the type I cell lines could spontaneously generate adherent cells in liquid culture, we next determined whether the adherent cells that arose might belong to the endothelial lineage. The adherent cells were examined for their ability to take up acetylated low-density lipoprotein (Ac-LDL), a characteristic of endothelial cells.14,15 In Figure 1F, it is shown that most adherent cells derived from the HOX11-immortalized precursor cells were capable of taking up fluorescenated Ac-LDL, DiI-Ac-LDL, even though the efficiency of dye uptake was lower than that of the positive control cells. To obtain further evidence in support of in vitro endothelial-like potential, the capacity of the precursor cell lines to form tubelike structures on basement membrane proteins was investigated. When type I precursor cells were seeded onto Matrigel-coated wells, a majority of the cells attached, aligned in tandem, and differentiated into tubelike or capillarylike structures (Figure 1Gi). In contrast, none of 10 HOX11-immortalized type II (hematopoietic) yolk sac cell lines lacking the ability to form adherent cells in liquid culture exhibited this phenotype (Figure 1Gii). Additionally, even though complete endothelial development of type I precursor cells could not be demonstrated, perhaps due to a HOX11-mediated differentiation block as a consequence of immortalization, a low percentage (3%-5%) of cells positive for VEGF receptors 2 (Flk-1) and 1 (Flt-1) were detected within the adherent endothelial-like cell population by FACS analyses (Figure 1H). These observations suggest that type I yolk sac precursor cells immortalized by HOX11 have a partial endothelial-like differentiation capacity. Northern blot analyses showed that type I yolk sac precursor cells
coexpressed transcription factors that play critical roles in early
hematopoietic and endothelial development such as SCL, GATA1, GATA2,
PU.1, and c-myb. Further characterization of the surface
phenotypes demonstrated that these cell lines were negative for Sca-1,
CD34, CD45, and CD18 plus all hematopoietic lineage markers tested
(Ter-119, Gr-1, Mac-1, B220, CD3, and Fc
The growth responsiveness of type I yolk sac precursor cell lines to various cytokines was next tested. As shown in Figure 2B, bFGF, VEGF, SCF, and IL-6 individually and in combination significantly enhanced colony formation of the precursor cells in serum-substituted methylcellulose medium. Collectively, the morphologic, phenotypic, and functional properties of type I yolk sac cells immortalized by HOX11 suggest that they represent a transitional stage biased toward the hematopoietic lineage. However, these yolk sac-derived cell lines also demonstrated partial endothelial-like potential. Whether this property represents in vitro transdifferentiation or is indicative of a hemangioblast origin remains to be determined.
We thank Drs Christian Haudenschild, Daniel A. Lawrence, Grainne McMahon, Kevin D. Bunting, Dorothea Scandella, and Mehrdad Tondravi for technical assistance and helpful comments on this work.
Submitted March 26, 2002; accepted June 24, 2002.
Prepublished online as Blood First Edition Paper, July 5, 2002; DOI 10.1182/blood-2002-03-0937.
Supported by funds from the National Institutes of Health grants R01 HL68212-01A1 (to C.-K.Q.) and R01 HL66305 (to R.G.H.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Cheng-Kui Qu, Department of Hematopoiesis, Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855; e-mail: quc{at}usa.redcross.org.
1. Keller G, Lacaud G, Robertson S. Development of the hematopoietic system in the mouse. Exp Hematol. 1999;27:777-787[CrossRef][Medline] [Order article via Infotrieve].
2.
Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ.
Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia.
Science.
1991;253:79-82 3. Lu M, Gong ZY, Shen WF, Ho AD. The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein. EMBO J. 1991;10:2905-2910[Medline] [Order article via Infotrieve].
4.
Kennedy MA, Gonzalez-Sarmiento R, Kees UR, et al.
HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24.
Proc Natl Acad Sci U S A.
1991;88:8900-8904 5. Hawley RG, Fong AZ, Lu M, Hawley TS. The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene. 1994;9:1-12[Medline] [Order article via Infotrieve].
6.
Hawley RG, Fong AZ, Reis MD, Zhang N, Lu M, Hawley TS.
Transforming function of the HOX11/TCL3 homeobox gene.
Cancer Res.
1997;57:337-345
7.
Keller G, Wall C, Fong AZ, Hawley TS, Hawley RG.
Overexpression of HOX11 leads to the immortalization of embryonic precursors with both primitive and definitive hematopoietic potential.
Blood.
1998;92:877-887
8.
Cantor AB, Katz SG, Orkin SH.
Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation.
Mol Cell Biol.
2002;22:4268-4279 9. Qu CK, Shi ZQ, Shen R, Tsai FY, Orkin SH, Feng GS. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol. 1997;17:5499-5507[Abstract].
10.
Qu CK, Yu WM, Azzarelli B, Cooper S, Broxmeyer HE, Feng GS.
Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells.
Mol Cell Biol.
1998;18:6075-6082
11.
Yu WM, Hawley TS, Hawley RG, Qu CK.
Role of the docking protein Gab2 in beta(1)-integrin signaling pathway-mediated hematopoietic cell adhesion and migration.
Blood.
2002;99:2351-2359 12. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature. 1980;288:551-556[CrossRef][Medline] [Order article via Infotrieve]. 13. Hatzopoulos AK, Folkman J, Vasile E, Eiselen GK, Rosenberg RD. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development. 1998;125:1457-1468[Abstract]. 14. Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000;408:92-96[CrossRef][Medline] [Order article via Infotrieve]. 15. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development. 1998;125:725-732[Abstract]. 16. Herrmann BG, Labeit S, Poustka A, King TR, Lehrach H. Cloning of the T gene required in mesoderm formation in the mouse. Nature. 1990;343:617-622[CrossRef][Medline] [Order article via Infotrieve]. 17. Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature. 1997;386:488-493[CrossRef][Medline] [Order article via Infotrieve]. 18. Robertson SM, Kennedy M, Shannon JM, Keller G. A transitional stage in the commitment of mesoderm to hematopoiesis requiring the transcription factor SCL/tal-1. Development. 2000;127:2447-2459[Abstract].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
Z.-j. Ye, Y. Kluger, Z. Lian, and S. M. Weissman Two types of precursor cells in a multipotential hematopoietic cell line PNAS, December 20, 2005; 102(51): 18461 - 18466. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Asnafi, K. Beldjord, M. Libura, P. Villarese, C. Millien, P. Ballerini, E. Kuhlein, M. Lafage-Pochitaloff, E. Delabesse, O. Bernard, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy Blood, December 15, 2004; 104(13): 4173 - 4180. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||